122 related articles for article (PubMed ID: 38552432)
1. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation.
Liu Q; Xu M; Qiu M; Yu J; Wang Q; Zhou Y; Lin Q; Cai X; Yang L; Zhao H; Zhao C; Xie X
Phytomedicine; 2024 Jun; 128():155538. PubMed ID: 38552432
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
Jin G; Ma M; Yang C; Zhen L; Feng M
Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
[TBL] [Abstract][Full Text] [Related]
4. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells.
Kim J; Jang H; Lee GJ; Hur Y; Keum J; Jo JK; Yun SE; Park SJ; Park YJ; Choi MJ; Kim KS; Kim J
Cells; 2021 Dec; 11(1):. PubMed ID: 35011581
[TBL] [Abstract][Full Text] [Related]
5. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
6. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
7. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
9. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
10. Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification.
Pan J; Yang H; Zhu L; Lou Y; Jin B
Front Pharmacol; 2022; 13():897966. PubMed ID: 36091822
[No Abstract] [Full Text] [Related]
11. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Yang A; Li MY; Zhang ZH; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Zuo HX; Ma J; Jin X
J Ethnopharmacol; 2021 Jun; 273():113598. PubMed ID: 33220359
[TBL] [Abstract][Full Text] [Related]
12. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
13. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
[TBL] [Abstract][Full Text] [Related]
14. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
15. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
17. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
[TBL] [Abstract][Full Text] [Related]
18. STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.
Chen J; Liu Y; Zhu Y; Chen Y; Feng J; Jiang T; Zheng X; Chen L; Jiang J
Clin Transl Oncol; 2022 May; 24(5):927-940. PubMed ID: 35107757
[TBL] [Abstract][Full Text] [Related]
19. HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Teng L; Wang K; Chen W; Wang YS; Bi L
Pharmacol Res; 2020 Oct; 160():105086. PubMed ID: 32687951
[TBL] [Abstract][Full Text] [Related]
20. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
